Top

Published in:

01-04-2016 | Original Article

Expression of the CXCR4 ligand SDF-1/CXCL12 is prognostically important for adenocarcinoma and large cell carcinoma of the lung

Authors: William Sterlacci, Shereen Saker, Bettina Huber, Michael Fiegl, Alexandar Tzankov

Published in: Virchows Archiv | Issue 4/2016

Abstract

The SDF-1/CXCR4 axis is associated with tumor progression and has been reported as a prognostic parameter, although with conflicting data for non-small cell lung cancer (NSCLC). This study examines a large cohort of clinically and pathologically well-characterized NSCLC patients and includes the activated form of CXCR4 (pCXCR4), which has not been studied in this context so far. SDF-1, CXCR4, and pCXCR4 were assessed immunohistochemically in 371 surgically resected NSCLC using a standardized tissue microarray platform. Extensive clinical and pathological data and a postoperative follow-up period of 17 years enabled detailed correlations. CXCR4 and pCXCR4 were frequently expressed on squamous cell carcinoma. Membranous expression of SDF-1 was a marker of poor prognosis and proved to be an independent prognostic parameter for the entire cohort and for patients with adenocarcinoma (ACA) and large cell carcinoma (LCC). Targeted cancer therapies blocking SDF-1/CXCR4 interaction already exist, and our data suggest that expression of SDF-1, especially on poorer prognosis subgroups of LCC and ACA, indicates patients that might benefit more than others. This should be taken into account when assessing the effectiveness of such targeted approaches for NSCLC patients and could lead to important implications.

Lovly CM, Carbone DP (2011) Lung cancer in 2010: one size does not fit all. Nat Rev Clin Oncol 8:68–70CrossRefPubMed

Siegel R, DeSantis C, Virgo K, Stein K et al (2012) Cancer treatment and survivorship statistics, 2012. CA Cancer J Clin 62:220–241CrossRefPubMed

Pallis AG, Serfass L, Dziadziusko R et al (2009) Targeted therapies in the treatment of advanced/metastatic NSCLC. Eur J Cancer 45:2473–2487CrossRefPubMed

Dempke WC, Suto TM, Reck M (2010) Targeted therapies for non-small cell lung cancer. Lung Cancer 67:257–274CrossRefPubMed

Raman D, Sobolik-Delmaire T, Richmond A (2011) Chemokines in health and disease. Exp Cell Res 317:575–589CrossRefPubMedPubMedCentral

Zlotnik A, Yoshie O (2000) Chemokines: a new classification system and their role in immunity. Immunity 12:121–127CrossRefPubMed

Murphy PM, Baggiolini M, Charo IF et al (2000) International union of pharmacology. XXII. Nomenclature for chemokine receptors. Pharmacol Rev 52:145–176PubMed

Kijima T, Maulik G, Ma PC et al (2002) Regulation of cellular proliferation, cytoskeletal function, and signal transduction through CXCR4 and c-Kit in small cell lung cancer cells. Cancer Res 62:6304–6311PubMed

Balkwill F (2004) Cancer and the chemokine network. Nat Rev Cancer 4:540–550CrossRefPubMed

10.

Barretina J, Juncà J, Llano A et al (2003) CXCR4 and SDF-1 expression in B-cell chronic lymphocytic leukemia and stage of the disease. Ann Hematol 82:500–505CrossRefPubMed

11.

Nomiyama H, Osada N, Yoshie O (2010) The evolution of mammalian chemokine genes. Cytokine Growth Factor Rev 21:253–262CrossRefPubMed

12.

Messmer D, Fecteau JF, O’Hayre M et al (2011) Chronic lymphocytic leukemia cells receive RAF-dependent survival signals in response to CXCL12 that are sensitive to inhibition by sorafenib. Blood 117:882–889CrossRefPubMedPubMedCentral

13.

Bertran E, Caja L, Navarro E et al (2009) Role of CXCR4/SDF-1 alpha in the migratory phenotype of hepatoma cells that have undergone epithelial-mesenchymal transition in response to the transforming growth factor-beta. Cell Signal 21:1595–1606CrossRefPubMed

14.

Spano JP, Andre F, Morat L et al (2004) Chemokine receptor CXCR4 and early-stage non-small cell lung cancer: pattern of expression and correlation with outcome. Ann Oncol 15:613–617CrossRefPubMed

15.

Phillips RJ, Burdick MD, Lutz M et al (2003) The stromal derived factor-1/CXCL12-CXC chemokine receptor 4 biological axis in non-small cell lung cancer metastases. Am J Respir Crit Care Med 167:1676–1686CrossRefPubMed

16.

Wagner PL, Hyjek E, Vazquez MF et al (2009) CXCL12 and CXCR4 in adenocarcinoma of the lung: association with metastasis and survival. J Thorac Cardiovasc Surg 137:615–621CrossRefPubMed

17.

Na IK, Scheibenbogen C, Adam C et al (2008) Nuclear expression of CXCR4 in tumor cells of non-small cell lung cancer is correlated with lymph node metastasis. Hum Pathol 39:1751–1755CrossRefPubMed

18.

Otsuka S, Klimowicz AC, Kopciuk K et al (2011) CXCR4 overexpression is associated with poor outcome in females diagnosed with stage IV non-small cell lung cancer. J Thorac Oncol 6:1169–1178CrossRefPubMed

19.

Franco R, Pirozzi G, Scala S et al (2012) CXCL12-binding receptors expression in non-small cell lung cancer relates to tumoral microvascular density and CXCR4 positive circulating tumoral cells in lung draining venous blood. Eur J Cardiothorac Surg 41:368–375CrossRefPubMed

20.

Wald O, Shapira OM, Izhar U (2013) CXCR4/CXCL12 axis in non small cell lung cancer (NSCLC) pathologic roles and therapeutic potential. Theranostics 3:26–33CrossRefPubMedPubMedCentral

21.

Su L, Zhang J, Xu H et al (2005) Differential expression of CXCR4 is associated with the metastatic potential of human non-small cell lung cancer cells. Clin Cancer Res 11:8273–8280CrossRefPubMed

22.

Wald O, Izhar U, Amir G, Avniel S et al (2006) CD4+CXCR4 high CD69+ T cells accumulate in lung adenocarcinoma. J Immunol 177:6983–6990CrossRefPubMed

23.

Oonakahara K, Matsuyama W, Higashimoto I et al (2004) Stromal-derived factor-1alpha/CXCL12-CXCR 4 axis is involved in the dissemination of NSCLC cells into pleural space. Am J Respir Cell Mol Biol 30:671–677CrossRefPubMed

24.

Sterlacci W, Fiegl M, Hilbe W et al (2009) Clinical relevance of neuroendocrine differentiation in non-small cell lung cancer assessed by immunohistochemistry: a retrospective study on 405 surgically resected cases. Virchows Arch 455:125–132CrossRefPubMed

25.

Sterlacci W, Savic S, Fiegl M et al (2014) Putative stem cell markers in non-small-cell lung cancer: a clinicopathologic characterization. J Thorac Oncol 9:41–49CrossRefPubMed

26.

Travis W, Brambilla E, Burke A et al (2015) WHO classification of tumours of the lung, pleura, thymus and heart. IARC Press, Lyon

27.

Kocher F, Hilbe W, Seeber A et al (2015) Longitudinal analysis of 2293 NSCLC patients: a comprehensive study from the TYROL registry. Lung Cancer 87:193–200CrossRefPubMed

28.

Brault L, Rovó A, Decker S et al (2014) CXCR4-SERINE339 regulates cellular adhesion, retention and mobilization, and is a marker for poor prognosis in acute myeloid leukemia. Leukemia 28:566–576CrossRefPubMed

29.

Sterlacci W, Wolf D, Savic S et al (2012) High transforming growth factor β expression represents an important prognostic parameter for surgically resected non-small cell lung cancer. Hum Pathol 43:339–349CrossRefPubMed

30.

Tzankov A, Zlobec I, Went P et al (2010) Prognostic immunophenotypic biomarker studies in diffuse large B cell lymphoma with special emphasis on rational determination of cut-off scores. Leuk Lymphoma 51:199–212CrossRefPubMed

31.

Sterlacci W, Tzankov A, Veits L et al (2011) The prognostic impact of sex on surgically resected non-small cell lung cancer depends on clinicopathologic characteristics. Am J Clin Pathol 135:611–618CrossRefPubMed

32.

Brault L, Menter T, Obermann EC et al (2012) PIM kinases are progression markers and emerging therapeutic targets in diffuse large B-cell lymphoma. Br J Cancer 24 107:491–500CrossRef

33.

Wald O, Izhar U, Amir G et al (2011) Interaction between neoplastic cells and cancer-associated fibroblasts through the CXCL12/CXCR4 axis: role in non-small cell lung cancer tumor proliferation. J Thorac Cardio vasc Surg 141:1503–1512CrossRef

34.

Jung Y, Kim JK, Shiozawa Y et al (2013) Recruitment of mesenchymal stem cells into prostate tumours promotes metastasis. Nat Commun 4:1795CrossRefPubMedPubMedCentral

35.

Huang YC, Hsiao YC, Chen YJ et al (2007) Stromal cell-derived factor-1 enhances motility and integrin up-regulation through CXCR4, ERK and NF-kappaB-dependent pathway in human lung cancer cells. Biochem Pharmacol 74:1702–1712CrossRefPubMed

36.

Wendt MK, Johanesen PA, Kang-Decker N et al (2006) Silencing of epithelial CXCL12 expression by DNA hypermethylation promotes colonic carcinoma metastasis. Oncogene 25:4986–4997CrossRefPubMedPubMedCentral

37.

Kobayashi T, Tsuda H, Moriya T et al (2010) Expression pattern of stromal cell-derived factor-1 chemokine in invasive breast cancer is correlated with estrogen receptor status and patient prognosis. Breast Cancer Res Treat 123:733–745CrossRefPubMed

38.

Suzuki M, Mohamed S, Nakajima T et al (2008) Aberrant methylation of CXCL12 in non-small cell lung cancer is associated with an unfavorable prognosis. Int J Oncol 33:113–119PubMed

39.

Xu J, Clark RA (1996) Extracellular matrix alters PDGF regulation of fibroblast integrins. J Cell Biol 132:239–249CrossRefPubMed

40.

Cojoc M, Peitzsch C, Trautmann F et al (2013) Emerging targets in cancer management: role of the CXCL12/CXCR4 axis. Onco Targets Ther 6:1347–1361PubMedPubMedCentral

41.

Pomme G, Augustin F, Fiegl M et al (2015) Detailed assessment of microvasculature markers in non-small cell lung cancer reveals potentially clinically relevant characteristics. Virchows Arch 467:55–66CrossRefPubMed

42.

Bertolini G, Roz L, Perego P et al (2009) Highly tumorigenic lung cancer CD133+ cells display stem-like features and are spared by cisplatin treatment. Proc Natl Acad Sci U S A 106:16281–16286CrossRefPubMedPubMedCentral

43.

Fujii N, Nakashima H, Tamamura H (2003) The therapeutic potential of CXCR4 antagonists in the treatment of HIV. Expert Opin Investig Drugs 12:185–195CrossRefPubMed

44.

Fahham D, Weiss ID, Abraham M et al (2012) In vitro and in vivo therapeutic efficacy of CXCR4 antagonist BKT140 against human non-small cell lung cancer. J Thorac Cardio vasc Surg 144:1167–1175CrossRef

45.

Kioi M, Vogel H, Schultz G et al (2010) Inhibition of vasculogenesis, but not angiogenesis, prevents the recurrence of glioblastoma after irradiation in mice. J Clin Invest 120:694–705CrossRefPubMedPubMedCentral

Title: Expression of the CXCR4 ligand SDF-1/CXCL12 is prognostically important for adenocarcinoma and large cell carcinoma of the lung
Authors: William Sterlacci
Shereen Saker
Bettina Huber
Michael Fiegl
Alexandar Tzankov
Publication date: 01-04-2016
Publisher: Springer Berlin Heidelberg
Published in: Virchows Archiv / Issue 4/2016
Print ISSN: 0945-6317
Electronic ISSN: 1432-2307
DOI: https://doi.org/10.1007/s00428-015-1900-y

At a glance: The STEP trials

Springer Medicine

Expression of the CXCR4 ligand SDF-1/CXCL12 is prognostically important for adenocarcinoma and large cell carcinoma of the lung

Abstract

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 4/2016

Consistency in recognizing microinvasion in breast carcinomas is improved by immunohistochemistry for myoepithelial markers

RAS testing in metastatic colorectal cancer: advances in Europe

Intrafollicular Epstein-Barr virus-positive large B cell lymphoma. A variant of “germinotropic” lymphoproliferative disorder

Prognostic significance of tumor regression in lymph nodes after neoadjuvant therapy for rectal carcinoma

Negative association between GATA3 and fascin could predict relapse-free and overall survival in patients with breast cancer

Funisitis is associated with adverse neonatal outcome in low-risk unselected deliveries at or near term